176 related articles for article (PubMed ID: 11579677)
1. High prevalence of RET tyrosine kinase activation in Mexican patients with papillary thyroid carcinomas.
Martínez I; Mantilla A; Medrano ME; Hernández R; Hernández DM; Lazos M; Santiago H; González B; Hidalgo A; Salcedo M
Endocr Pathol; 2001; 12(2):113-23. PubMed ID: 11579677
[TBL] [Abstract][Full Text] [Related]
2. The RET proto-oncogene in medullary and papillary thyroid carcinoma. Molecular features, pathophysiology and clinical implications.
Komminoth P
Virchows Arch; 1997 Jul; 431(1):1-9. PubMed ID: 9247627
[TBL] [Abstract][Full Text] [Related]
3. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.
Puxeddu E; Moretti S; Giannico A; Martinelli M; Marino C; Avenia N; Cristofani R; Farabi R; Reboldi G; Ribacchi R; Pontecorvi A; Santeusanio F
Eur J Endocrinol; 2003 May; 148(5):505-13. PubMed ID: 12720532
[TBL] [Abstract][Full Text] [Related]
4. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes.
Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A
Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913
[TBL] [Abstract][Full Text] [Related]
5. RET oncogene activation in papillary thyroid carcinoma.
Tallini G; Asa SL
Adv Anat Pathol; 2001 Nov; 8(6):345-54. PubMed ID: 11707626
[TBL] [Abstract][Full Text] [Related]
6. [Rearrangement of the RET gene in papillary thyroid carcinoma].
Wiench M; Włoch J; Oczko M; Gubała E; Jarzab B
Wiad Lek; 2001; 54 Suppl 1():64-71. PubMed ID: 12182064
[TBL] [Abstract][Full Text] [Related]
7. Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas.
Lanzi C; Borrello MG; Bongarzone I; Migliazza A; Fusco A; Grieco M; Santoro M; Gambetta RA; Zunino F; Della Porta G
Oncogene; 1992 Nov; 7(11):2189-94. PubMed ID: 1437145
[TBL] [Abstract][Full Text] [Related]
8. ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?
Sugg SL; Zheng L; Rosen IB; Freeman JL; Ezzat S; Asa SL
J Clin Endocrinol Metab; 1996 Sep; 81(9):3360-5. PubMed ID: 8784097
[TBL] [Abstract][Full Text] [Related]
9. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
10. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults.
Elisei R; Romei C; Vorontsova T; Cosci B; Veremeychik V; Kuchinskaya E; Basolo F; Demidchik EP; Miccoli P; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3211-6. PubMed ID: 11443191
[TBL] [Abstract][Full Text] [Related]
11. RET/PTC rearrangement in thyroid tumors.
Nikiforov YE
Endocr Pathol; 2002; 13(1):3-16. PubMed ID: 12114746
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of papillary thyroid carcinoma is facilitated by using an RT-PCR approach on laser-microdissected archival material to detect RET oncogene activation.
Lahr G; Stich M; Schütze K; Blümel P; Pösl H; Nathrath WB
Pathobiology; 2000; 68(4-5):218-26. PubMed ID: 11279350
[TBL] [Abstract][Full Text] [Related]
13. Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.
Fabien N; Paulin C; Santoro M; Berger N; Grieco M; Galvain D; Barbier Y; Dubois PM; Fusco A
Br J Cancer; 1992 Dec; 66(6):1094-8. PubMed ID: 1457350
[TBL] [Abstract][Full Text] [Related]
14. RET/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas.
Learoyd DL; Messina M; Zedenius J; Guinea AI; Delbridge LW; Robinson BG
J Clin Endocrinol Metab; 1998 Oct; 83(10):3631-5. PubMed ID: 9768676
[TBL] [Abstract][Full Text] [Related]
15. RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions.
Collins BJ; Chiappetta G; Schneider AB; Santoro M; Pentimalli F; Fogelfeld L; Gierlowski T; Shore-Freedman E; Jaffe G; Fusco A
J Clin Endocrinol Metab; 2002 Aug; 87(8):3941-6. PubMed ID: 12161537
[TBL] [Abstract][Full Text] [Related]
16. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
17. Low rate of ret proto-oncogene activation (PTC/retTPC) in papillary thyroid carcinomas from Saudi Arabia.
Zou M; Shi Y; Farid NR
Cancer; 1994 Jan; 73(1):176-80. PubMed ID: 8275421
[TBL] [Abstract][Full Text] [Related]
18. High frequency of rearrangement of the RET protooncogene (RET/PTC) in Chinese papillary thyroid carcinomas.
Lee CH; Hsu LS; Chi CW; Chen GD; Yang AH; Chen JY
J Clin Endocrinol Metab; 1998 May; 83(5):1629-32. PubMed ID: 9589668
[TBL] [Abstract][Full Text] [Related]
19. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
[TBL] [Abstract][Full Text] [Related]
20. Ret oncogene activation in papillary thyroid carcinoma: prevalence and implication on the histological parameters.
Lam AK; Montone KT; Nolan KA; Livolsi VA
Hum Pathol; 1998 Jun; 29(6):565-8. PubMed ID: 9635675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
